Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

ClinicalTrials.gov ID: NCT05143840

Public ClinicalTrials.gov record NCT05143840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)

Study identification

NCT ID: NCT05143840
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Augusta University; Other
Enrollment: 100 participants

Conditions and interventions

Conditions

Interventions

Elective Free Treatment Other
Low TKI Combination Product
Single Agent Asciminib Drug

Other · Combination Product · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 21, 2022
Primary completion: Jan 31, 2032
Completion: Jan 31, 2032
Last update posted: Mar 22, 2026

2022 – 2032

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
Winship Cancer Institute Emory University	Atlanta	Georgia	30322	Recruiting
Georgia Cancer Center at Augusta University	Augusta	Georgia	30912	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14263	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting
Froedtert Hospital & the Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05143840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 22, 2026 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05143840 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →